These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
105 related articles for article (PubMed ID: 7751047)
41. Poor clinical course in a child with myelodysplastic syndrome and del(13)(q14q22). Oren H; Yüksel E; Yilmaz S; Türker M; Demircioğlu F; Irken G Cancer Genet Cytogenet; 2005 Nov; 163(1):74-6. PubMed ID: 16271960 [TBL] [Abstract][Full Text] [Related]
42. Prognosis of patients with del(5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Giagounidis AA; Germing U; Strupp C; Hildebrandt B; Heinsch M; Aul C Ann Hematol; 2005 Sep; 84(9):569-71. PubMed ID: 15891887 [TBL] [Abstract][Full Text] [Related]
43. Better prognosis for patients with del(7q) than for patients with monosomy 7 in myelodysplastic syndrome. Cordoba I; González-Porras JR; Nomdedeu B; Luño E; de Paz R; Such E; Tormo M; Vallespi T; Collado R; Xicoy B; Andreu R; Muñoz JA; Solé F; Cervera J; del Cañizo C; Cancer; 2012 Jan; 118(1):127-33. PubMed ID: 21717439 [TBL] [Abstract][Full Text] [Related]
44. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. Nimer SD J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711 [TBL] [Abstract][Full Text] [Related]
45. Multiplex fluorescence in situ hybridization in identifying chromosome involvement of complex karyotypes in de novo myelodysplastic syndromes and acute myeloid leukemia. Xu W; Li JY; Liu Q; Zhu Y; Pan JL; Qiu HR; Xue YQ Int J Lab Hematol; 2010 Feb; 32(1 Pt 1):e86-95. PubMed ID: 20089000 [TBL] [Abstract][Full Text] [Related]
46. Molecular definition of chromosome arm 5q deletion end points and detection of hidden aberrations in patients with myelodysplastic syndromes and isolated del(5q) using oligonucleotide array CGH. Evers C; Beier M; Poelitz A; Hildebrandt B; Servan K; Drechsler M; Germing U; Royer HD; Royer-Pokora B Genes Chromosomes Cancer; 2007 Dec; 46(12):1119-28. PubMed ID: 17823930 [TBL] [Abstract][Full Text] [Related]
47. Karyotypic identification of abnormal clones preceding morphological changes or occurring with no definite morphological features of myelodysplastic syndrome: a preliminary study. Han JY; Theil KS Lab Hematol; 2007; 13(1):17-21. PubMed ID: 17353178 [TBL] [Abstract][Full Text] [Related]
48. Cytogenetic features of 5q deletion and 5q- syndrome in myelodysplastic syndrome in Korea; marker chromosomes proved to be chromosome 5 with interstitial deletion by fluorescence in situ hybridization. Lee HR; Oh B; Hong DS; Zang DY; Yoon HJ; Kim HJ; Kim I; Ahn JS; Cheong JW; Lee KA; Cho KS; Lee MH; Bang SM; Kim TY; Yun YM; Min YH; Lee YK; Lee DS; Cancer Genet Cytogenet; 2010 Dec; 203(2):193-202. PubMed ID: 21156233 [TBL] [Abstract][Full Text] [Related]
49. [Cytogenetic findings in patients with primary myelodysplastic syndrome and their prognostic significance. (Analysis of results in 65 patients)]. Indrák K; Jarosová M; Sulovská I; Scudla V; Hubácek J; Sousková I; Bĕhal K; Svobodová M Vnitr Lek; 1994 Sep; 40(9):577-85. PubMed ID: 7975361 [TBL] [Abstract][Full Text] [Related]
51. Chromosomal aberrations in congenital bone marrow failure disorders--an early indicator for leukemogenesis? Göhring G; Karow A; Steinemann D; Wilkens L; Lichter P; Zeidler C; Niemeyer C; Welte K; Schlegelberger B Ann Hematol; 2007 Oct; 86(10):733-9. PubMed ID: 17653548 [TBL] [Abstract][Full Text] [Related]
52. [Chromosomal abnormalities in malignant hematologic diseases]. Rojas A; Pineda L; González S; Soto M; Avila E; Urdaneta B; Prieto-Carrasquero M; González R Acta Cient Venez; 2000; 51(2):109-14. PubMed ID: 11155855 [TBL] [Abstract][Full Text] [Related]
53. Cytogenetic as an important tool for diagnosis and prognosis for patients with hypocellular primary myelodysplastic syndrome. de Souza DC; Fernandez Cde S; Camargo A; Apa AG; da Costa ES; Bouzas LF; Abdelhay E; Fernandez Tde S Biomed Res Int; 2014; 2014():542395. PubMed ID: 25180186 [TBL] [Abstract][Full Text] [Related]
54. [The relevance between quantitative and type of chromosomal abnormality and leukemia transformation in myelodysplastic syndrome]. Li Y; Li WW; Wang XM; An L; Liu H; Wang ZS; Xiao ZJ; Qin TJ Zhonghua Xue Ye Xue Za Zhi; 2013 Mar; 34(3):221-4. PubMed ID: 23683420 [TBL] [Abstract][Full Text] [Related]
55. Spectrum of complex chromosomal aberrations in a myelodysplastic syndrome and a brief review. Ganguly BB; Dolai TK; De R; Kadam NN J Cancer Res Ther; 2016; 12(3):1203-1206. PubMed ID: 28054536 [TBL] [Abstract][Full Text] [Related]
56. Cytogenetic survey of 117 Tunisian patients with de novo myelodysplastic syndrome. Sendi HS; Hichri H; Elghezal H; Gribaa M; Laatiri A; Elloumi M; Ben Lakhal R; Saad A Ann Genet; 2002; 45(3):131-5. PubMed ID: 12381443 [TBL] [Abstract][Full Text] [Related]
57. Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression. Fernandez-Mercado M; Pellagatti A; Di Genua C; Larrayoz MJ; Winkelmann N; Aranaz P; Burns A; Schuh A; Calasanz MJ; Cross NC; Boultwood J Br J Haematol; 2013 Oct; 163(2):235-9. PubMed ID: 23889083 [TBL] [Abstract][Full Text] [Related]
59. Cytogenetic analysis of 52 Indian patients with de novo myelodysplastic syndromes-a comparative analysis of results with reports from Asia. Dakshinamurthy AG; Novitzky N; Bharadwaj R; Prakhya BM Ann Hematol; 2005 May; 84(5):298-303. PubMed ID: 15742188 [TBL] [Abstract][Full Text] [Related]
60. Cytogenetics of secondary myelodysplasia (sMDS) and acute nonlymphocytic leukemia (sANLL). Johansson B; Mertens F; Heim S; Kristoffersson U; Mitelman F Eur J Haematol; 1991 Jul; 47(1):17-27. PubMed ID: 1868912 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]